Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$2.13 - $3.74 $21,659 - $38,032
10,169 New
10,169 $28,000
Q3 2020

Nov 16, 2020

SELL
$2.63 - $8.09 $70,810 - $217,815
-26,924 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$5.69 - $8.17 $153,197 - $219,969
26,924 New
26,924 $179,000
Q1 2020

May 15, 2020

SELL
$5.47 - $11.3 $15,655 - $32,340
-2,862 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$7.07 - $11.61 $20,234 - $33,227
2,862 New
2,862 $26,000
Q1 2019

May 15, 2019

SELL
$9.97 - $18.96 $284,234 - $540,530
-28,509 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$11.61 - $31.1 $330,989 - $886,629
28,509 New
28,509 $440,000

Others Institutions Holding GRTS

About Gritstone bio, Inc.


  • Ticker GRTS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,006,896
  • Market Cap $2.19M
  • Description
  • Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...
More about GRTS
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.